Vor Biopharma Inc. Stock Price, News & Analysis

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company focused on autoimmune disease treatments, has announced its participation in two upcoming investor conferences. The company will participate in a fireside chat at Citi's 2025 Biopharma Back to School Conference on September 2nd, 2025, at 11:15am ET in Boston. Additionally, Vor Bio will hold one-on-one investor meetings at the Baird 2025 Global Healthcare Conference on September 9th, 2025, in New York.

A live webcast of the Citi conference fireside chat will be accessible through the company's investor relations website at www.vorbio.com, where an archived replay will also be available.

Vor Bio (Nasdaq: VOR), a clinical-stage biotech company, announced inducement grants to seven new employees between August 4-18, 2025. The grants include 6,959,013 stock options and 1,491,217 restricted stock units (RSUs).

The stock options have exercise prices of $2.04-$2.11 per share with a ten-year term. Both options and RSUs follow a four-year vesting schedule, with 25% vesting after 12 months, followed by monthly vesting for options and quarterly vesting for RSUs over the next 36 months. These grants were made under the Vor Biopharma Inc. 2023 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).

Vor Bio (Nasdaq: VOR) announced that its collaborator RemeGen achieved the primary endpoint in a Phase 3 clinical study for telitacicept in treating primary Sjögren's disease. The study demonstrated that telitacicept significantly improved disease activity as measured by ESSDAI (EULAR Sjögren's syndrome disease activity index) compared to placebo, while maintaining a favorable safety profile.

RemeGen plans to submit a Biologics License Application (BLA) to Chinese regulators, which would make this telitacicept's fourth approved indication in China. The dual BAFF/APRIL inhibitor targets both upstream and downstream autoimmune signaling, potentially offering disease-modifying benefits rather than just symptom management.

Vor Bio (Nasdaq: VOR) has appointed Dallan Murray as Chief Commercial Officer, effective immediately. Murray brings over 25 years of experience in commercial strategy and global product launches from companies including Sarepta Therapeutics, where he achieved $1.8 billion in net product revenue in 2024.

Murray's extensive experience includes successful launches at major biotech companies, notably INCIVEK at Vertex Pharmaceuticals (fastest biotech launch to reach $1 billion), and strategic roles at Gilead Sciences, Biogen, and Johnson & Johnson. At Vor Bio, he will focus on commercialization strategy for telitacicept, which is currently approved in China for multiple autoimmune indications and advancing through global Phase 3 development.

Vor Bio (Nasdaq: VOR) has strengthened its Board of Directors with the appointment of two biotech industry veterans: Alexander (Bo) Cumbo and Michel Detheux, Ph.D., effective July 16, 2025. Cumbo, currently President and CEO of Solid Biosciences, brings over 30 years of commercial and executive leadership experience, including his role as Executive VP and Chief Commercial Officer at Sarepta Therapeutics.

Dr. Detheux, President and CEO of iTeos Therapeutics, brings significant achievements including raising over $1 billion in capital and securing a $2 billion partnership with GSK. These appointments aim to support Vor Bio's advancement of telitacicept through late-stage development and expand its vision in autoimmune disease treatment.

Vor Bio (Nasdaq: VOR), a clinical-stage biotech company, has granted significant equity incentives to its new Chief Development Officer, Dr. Qing Zuraw. The compensation package includes 4,373,040 stock options at an exercise price of $2.38 per share and 937,080 restricted stock units (RSUs).

The grants, effective July 17, 2025, were made under the Vor Biopharma Inc. 2023 Inducement Plan as a material inducement to employment, complying with Nasdaq Listing Rule 5635(c)(4). The stock options have a 10-year term with a four-year vesting schedule, while RSUs will vest quarterly over four years, starting August 1, 2026.

Vor Bio (Nasdaq: VOR) has appointed Dr. Qing Zuraw as Chief Development Officer, bringing over 25 years of experience in global clinical development. Dr. Zuraw most recently served as Chief Development Officer at RemeGen, where she led the successful development of telitacicept across multiple autoimmune indications, securing regulatory approvals in China for SLE, generalized MG, and RA treatments.

At RemeGen, Dr. Zuraw managed clinical trial design, regulatory strategy, and achieved Fast Track, Breakthrough Therapy, and Orphan Drug designations. Her previous experience includes senior roles at Janssen, Teva, Akebia, Biogen, and Covance, where she contributed to multiple NDA and BLA submissions and the FDA approval of Guselkumab for psoriatic arthritis.

This strategic appointment aims to strengthen Vor Bio's execution of late-stage programs and global development initiatives, particularly in the U.S. market.

Vor Bio (Nasdaq: VOR) has appointed Sandy Mahatme as Chief Financial Officer and Chief Business Officer, effective July 9, 2025. Mahatme brings over 30 years of executive leadership experience in the biopharmaceutical industry, most recently serving as President, COO, and CFO of National Resilience, where he raised over $2.5 billion in capital.

At his previous role at Sarepta Therapeutics, Mahatme led capital formation efforts exceeding $3.5 billion and expanded the company's pipeline through strategic initiatives. The appointment comes as Vor Bio advances telitacicept through global Phase 3 development for generalized myasthenia gravis, with the drug already approved in China for multiple autoimmune indications.

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company focused on autoimmune disease treatments, has granted its new Chief Executive Officer Jean-Paul Kress a significant stock option award. The inducement grant, approved on June 26, 2025, includes options to purchase 83,296,638 shares of common stock at an exercise price of $0.89 per share.

The stock option, granted under the Vor Biopharma Inc. 2023 Inducement Plan, has a ten-year term and follows a four-year vesting schedule. The vesting includes a 25% cliff after the first year, followed by monthly vesting over the subsequent 36 months, contingent on Dr. Kress's continued employment.